IL17F and in situ carcinoma: However, a subgroup of CIS and MS patients producing over 250 pg/ml of IL-17F had significantly higher levels than HC (CIS, p = 0.0038; RRMS, p < 0.0001; SPMS, p = 0.0038; PPMS, p = 0.0004; Figure 1F).